US Brand Name(s): Blincyto

Use in Cancer Treatment

Blinatumomab is authorized to treat the following conditions:

Adults and children with B-cell acute lymphoblastic leukemia. It’s utilized in people whose cancer has recurred (returned) or is resistant to other treatments (does not respond to treatment).

Some patients with cancer that has gone into complete remission. The FDA’s Accelerated Approval Program has authorized this usage. A confirmatory study (or trials) must prove that blinatumomab has a therapeutic benefit in these individuals as a condition of approval.

Blinatumomab is also being researched for use in the treatment of other cancers.


A single-chain recombinant anti-CD19/anti-CD3 bispecific monoclonal antibody with immunostimulatory and anti-cancer properties. Blinatumomab has two antigen-recognition sites: one for the CD3 complex, a collection of T cell surface glycoproteins that interact with the TCR, and another for CD19, a tumor-associated antigen (TAA) overexpressed on B cell surfaces. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells, cytotoxic T lymphocytes (CTLs), and helper T lymphocytes (HTLs) together, potentially resulting in CD19-expressing B-lymphocytes being killed by CTLs and HTLs.

Blinatumomab Facts on – MedlinePlus

A summary of key information regarding this medication in layman’s terms, which may contain the following:

Cautions about this medicine, what it’s used for and how it’s used, what you should tell your doctor before taking it, what you should know about it before using it, other drugs that might interact with it, and possible negative effects.

Drugs are frequently investigated to see whether they can assist treat or prevent conditions other than those for which they have been authorized. Only authorized uses of the medication are covered by this patient information leaflet. Much of the material, though, might also apply to authorized uses that are being investigated.